---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-26-000044"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2026-07-28T11:04:40+00:00"
generated_at: "2026-07-28T11:05:05.209491+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Altimmune reports positive Phase 2 RECLAIM trial of pemvidutide in alcohol use disorder

## Summary
- Primary endpoint met: reduction in heavy drinking days/week vs placebo (LS mean diff -1.45, p=0.0014).
- 64.4% of pemvidutide patients achieved 2-level reduction in WHO Risk Drinking Level vs 34.8% placebo (p=0.0049).
- Zero heavy drinking days in 42.2% of pemvidutide patients vs 17.4% placebo (p=0.0066).
- Placebo-adjusted body weight reduction of 9.1% at 24 weeks (p<0.0001); no plateauing observed.
- Company plans to request End-of-Phase 2 meeting with FDA based on these results.

## SEC filing metadata
- accession: 0001326190-26-000044
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2026-07-28T11:04:40+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000044/0001326190-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000044/alt-20260728x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-26-000044
- JSON: https://secwatch.observer/filing/0001326190-26-000044.json
- Plain text: https://secwatch.observer/filing/0001326190-26-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.